You searched for: toxin (Maltesiska - Engelska)

millilitru fih 5000 u botulinum toxin tip b.
one ml contains 5000 u botulinum toxin type b.

millilitru fih 5000 u ta ’ botulinum toxin tip b.
one ml contains 5000 u botulinum toxin type b.

- is- sustanza attiva hija botulinum toxin tip b.
- the active substance is botulinum toxin type b.

pazjenti b’ espożizzjoni minn qabel għal botulinum toxin tip a
patients with prior botulinum toxin type a exposure

clinicoimmunologic aspects of botulinum toxin type b treatment of cervical dystonia.
clinicoimmunologic aspects of botulinum toxin type b treatment of cervical dystonia.

millilitru fih 5000 u botulinum toxin tip b (2500 u kull kunjett)
one ml contains 5000 u botulinum toxin type b (2500 u per vial)

neurobloc 5000 u/ ml soluzzjoni għall- injezzjoni botulinum toxin tip b
information for the user neurobloc 5000 u/ ml solution for injection botulinum toxin type b

millilitru fih 5000 u ta ’ botulinum toxin tip b (5000 u kull kunjett)
one ml contains 5000 u botulinum toxin type b (5000 u per vial)

mhux magħruf jekk botulinum toxin tip b joħroġx fil- ħalib tas- sider uman.
it is unknown whether botulinum toxin type b is excreted in human breast milk.

millilitru fih 5000 u ta ’ botulinum toxin tip b (10, 000 u kull kunjett)
one ml contains 5000 u of botulinum toxin type b (10,000 u per vial)

it- tneħħija ta ’ botulinum toxin tip b fil- ħalib ma ġietx studjata fl- annimali.
the excretion of botulinum toxin type b in milk has not been studied in animals.

madankollu, fi provi kliniċi, neurobloc ġie mogħti 16- il ġimgħa wara l- injezzjoni ta ’ botulinum toxin tip a.
however, in clinical trials, neurobloc was administered 16 weeks after the injection of botulinum toxin type a.

the use of botulinum toxin type- b in the treatment of patients who have become unresponsive to botulinum toxin type- a -- initial experiences.
the use of botulinum toxin type-b in the treatment of patients who have become unresponsive to botulinum toxin type-a -- initial experiences.

ara sezzjoni 5. 1 għall- informazzjoni dwar l- effikaċja f’ pazjenti li jirrispondu / jirreżistu għal botulinum toxin tip a.
see section 5.1 for data on efficacy in patients responsive / resistant to botulinum toxin type a.

f’konċentrazzjoni fil-plażma klinikament rilevanti, velpatasvir mhuwiex inibitur tat-trasportaturi epatiċi tal-pompa li tesporta l-melħ biljari (bsep, bile salt export pump), il-proteina kotrasportatur tas-sodium taurocholate (ntcp), oatp2b1, oatp1a2 jew it- trasportatur tal-cations organiċi (oct) 1, it-trasportaturi renali oct2, oat1, oat3, il-proteina 2 assoċjata mar-reżistenza għal ħafna mediċini (mrp2, multidrug resistance-associated protein 2) jew il- proteina ta’ estrużjoni ta’ ħafna mediċini u tat-tossini (mate, multidrug and toxin extrusion protein) 1, jew l-enzimi cyp jew uridine glucuronosyltransferase (ugt) 1a1.
at clinically relevant plasma concentration, velpatasvir is not an inhibitor of hepatic transporters bile salt export pump (bsep), sodium taurocholate cotransporter protein (ntcp), oatp2b1, oatp1a2 or organic cation transporter (oct) 1, renal transporters oct2, oat1, oat3, multidrug resistance-associated protein 2 (mrp2) or multidrug and toxin extrusion protein (mate) 1, or cyp or uridine glucuronosyltransferase (ugt) 1a1 enzymes.